Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0IOMGE)
| ADC Name |
JNJ-89862175
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
JNJ-89862175 ;JNJ-89862175;JNJ-2175
Click to Show/Hide
|
|||||
| Organization |
Johnson & Johnson (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-ENPP3 antibody
|
Antibody Info | ||||
| Antigen Name |
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Payload Target |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Lung cancer | ||||
| Ovarian cancer | ||||
| Endometrial cancer | ||||
| Kidney cancer |